The daily business briefing: August 26, 2021

Johnson & Johnson's COVID booster, Delta's surcharge for unvaccinated employees, and more

The J&J vaccine
(Image credit: JUSTIN TALLIS/AFP via Getty Images)

1. J&J: COVID booster shot increased antibodies 9-fold

Johnson & Johnson said Wednesday that booster shots for its one-dose coronavirus vaccine produced a nine-fold increase in antibodies compared to 28 days after the first shot. The company said the data came from two Phase 2 studies conducted in the United States and Europe in which some of the roughly 2,000 participants got booster doses six months after their first shots. "We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months," Dr. Mathai Mammen, global head of research and development for Janssen, said in a statement. "With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.